Pricing Deregulation: 340B Pharmacy Policy, Medicaid Payment Rules May Be Withdrawn
Trump administration's drug pricing action plan considers withdrawing guidance and whole or parts of rules that biopharma has opposed.
You may also be interested in...
Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.
Trump administration briefing materials show that the pharmaceutical industry's complaints about FDA's quality metrics initiative are getting high-level attention.
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.